MaaT Pharma SA of France expects to make its first regulatory submission to the European Medicines Agency in June following a successful Phase 3 trial of its microbiome therapy and a capital increase of €13 million from a private share placement. The capital increase was announced on 27 March, not long after the company reported the latest clinical data for its therapy. The therapy, MaaT013, is being developed for patients with acute graft-versus-host disease with gastrointestinal involvement.
